| Literature DB >> 30293453 |
Fei Hu1, Xiaohui Qiu2, Shizhong Bu1.
Abstract
Islet dysfunction is a hallmark of type 2 diabetes mellitus (T2DM). Compelling evidence suggests that accumulation of islet amyloid in the islets of Langerhans significantly contribute to β-cell dysfunction and diabetes. Emerging evidence implicates a role for cystic fibrosis transmembrane-conductance regulator in the regulation of insulin secretion from pancreatic islets. Impaired first-phase insulin responses and glucose homeostasis have also been reported in cystic fibrosis patients. The transforming growth factor-β protein superfamily is central regulators of pancreatic cell function, and has a key role in pancreas development and pancreatic disease, including diabetes and islet dysfunction. It is also becoming clear that islet inflammation plays a key role in the development of islet dysfunction. Inflammatory changes, including accumulation of macrophages, have been documented in type 2 diabetic islets. Islet dysfunction leads to hyperglycemia and ultimately the development of diabetes. In this review, we describe these risk factors and their associations with islet dysfunction.Entities:
Keywords: Islet dysfunction; cystic fibrosis transmembrane conductance regulator; islet amyloid polypeptide; islet inflammation; transforming growth factor-β; type 2 diabetes mellitus
Mesh:
Substances:
Year: 2018 PMID: 30293453 DOI: 10.1080/13813455.2018.1510967
Source DB: PubMed Journal: Arch Physiol Biochem ISSN: 1381-3455 Impact factor: 4.076